カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/03/23 | 1,426 | 1,434 | 1,389 | 1,390 | -37 | -2.6% | 82,800 |
2021/03/22 | 1,380 | 1,437 | 1,380 | 1,427 | +48 | +3.5% | 107,300 |
2021/03/19 | 1,395 | 1,399 | 1,367 | 1,379 | -26 | -1.9% | 99,000 |
2021/03/18 | 1,399 | 1,411 | 1,382 | 1,405 | -3 | -0.2% | 41,500 |
2021/03/17 | 1,378 | 1,414 | 1,363 | 1,408 | +41 | +3% | 41,800 |
2021/03/16 | 1,377 | 1,381 | 1,356 | 1,367 | -4 | -0.3% | 27,300 |
2021/03/15 | 1,360 | 1,375 | 1,340 | 1,371 | +8 | +0.6% | 31,700 |
2021/03/12 | 1,338 | 1,366 | 1,326 | 1,363 | +25 | +1.9% | 36,200 |
2021/03/11 | 1,332 | 1,339 | 1,305 | 1,338 | +5 | +0.4% | 35,600 |
2021/03/10 | 1,301 | 1,345 | 1,301 | 1,333 | +22 | +1.7% | 42,800 |
2021/03/09 | 1,319 | 1,319 | 1,290 | 1,311 | +4 | +0.3% | 55,100 |
2021/03/08 | 1,330 | 1,343 | 1,294 | 1,307 | -1 | -0.1% | 51,200 |
2021/03/05 | 1,315 | 1,321 | 1,283 | 1,308 | -22 | -1.7% | 71,700 |
2021/03/04 | 1,354 | 1,354 | 1,301 | 1,330 | -27 | -2% | 89,900 |
2021/03/03 | 1,371 | 1,386 | 1,356 | 1,357 | -29 | -2.1% | 39,400 |
2021/03/02 | 1,417 | 1,431 | 1,362 | 1,386 | -38 | -2.7% | 89,300 |
2021/03/01 | 1,417 | 1,452 | 1,402 | 1,424 | +13 | +0.9% | 49,200 |
2021/02/26 | 1,420 | 1,434 | 1,401 | 1,411 | -47 | -3.2% | 56,400 |
2021/02/25 | 1,442 | 1,461 | 1,421 | 1,458 | +20 | +1.4% | 59,000 |
2021/02/24 | 1,468 | 1,477 | 1,430 | 1,438 | -43 | -2.9% | 83,400 |
2021/02/22 | 1,435 | 1,493 | 1,435 | 1,481 | +65 | +4.6% | 104,300 |
2021/02/19 | 1,415 | 1,442 | 1,392 | 1,416 | -23 | -1.6% | 89,900 |
2021/02/18 | 1,421 | 1,455 | 1,410 | 1,439 | +3 | +0.2% | 91,600 |
2021/02/17 | 1,340 | 1,445 | 1,338 | 1,436 | +79 | +5.8% | 146,600 |
2021/02/16 | 1,418 | 1,418 | 1,356 | 1,357 | -65 | -4.6% | 149,800 |
2021/02/15 | 1,435 | 1,449 | 1,388 | 1,422 | -112 | -7.3% | 237,100 |
2021/02/12 | 1,549 | 1,556 | 1,530 | 1,534 | -39 | -2.5% | 86,600 |
2021/02/10 | 1,501 | 1,573 | 1,496 | 1,573 | +53 | +3.5% | 108,600 |
2021/02/09 | 1,551 | 1,551 | 1,494 | 1,520 | -23 | -1.5% | 155,900 |
2021/02/08 | 1,547 | 1,593 | 1,523 | 1,543 | +34 | +2.3% | 288,300 |
2021/02/05 | 1,420 | 1,516 | 1,420 | 1,509 | +81 | +5.7% | 223,500 |
2021/02/04 | 1,433 | 1,452 | 1,418 | 1,428 | -5 | -0.3% | 56,300 |
2021/02/03 | 1,392 | 1,462 | 1,392 | 1,433 | +45 | +3.2% | 177,000 |
2021/02/02 | 1,349 | 1,400 | 1,337 | 1,388 | +37 | +2.7% | 119,500 |
2021/02/01 | 1,319 | 1,352 | 1,301 | 1,351 | +20 | +1.5% | 52,500 |
2021/01/29 | 1,363 | 1,381 | 1,324 | 1,331 | -39 | -2.8% | 93,700 |
2021/01/28 | 1,321 | 1,375 | 1,321 | 1,370 | +8 | +0.6% | 62,300 |
2021/01/27 | 1,329 | 1,362 | 1,322 | 1,362 | +27 | +2% | 49,500 |
2021/01/26 | 1,379 | 1,379 | 1,335 | 1,335 | -43 | -3.1% | 68,700 |
2021/01/25 | 1,350 | 1,382 | 1,333 | 1,378 | +31 | +2.3% | 67,700 |
2021/01/22 | 1,363 | 1,374 | 1,341 | 1,347 | -16 | -1.2% | 63,400 |
2021/01/21 | 1,350 | 1,364 | 1,325 | 1,363 | +22 | +1.6% | 91,200 |
2021/01/20 | 1,310 | 1,351 | 1,298 | 1,341 | +36 | +2.8% | 119,500 |
2021/01/19 | 1,280 | 1,308 | 1,270 | 1,305 | +40 | +3.2% | 64,400 |
2021/01/18 | 1,313 | 1,313 | 1,256 | 1,265 | -41 | -3.1% | 87,700 |
2021/01/15 | 1,236 | 1,310 | 1,234 | 1,306 | +67 | +5.4% | 170,600 |
2021/01/14 | 1,235 | 1,246 | 1,230 | 1,239 | -2 | -0.2% | 59,300 |
2021/01/13 | 1,233 | 1,245 | 1,225 | 1,241 | -5 | -0.4% | 33,300 |
2021/01/12 | 1,231 | 1,246 | 1,216 | 1,246 | +11 | +0.9% | 56,800 |
2021/01/08 | 1,210 | 1,235 | 1,205 | 1,235 | +36 | +3% | 111,200 |
901~
950
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム